Used in the treatment of neovascular age-related macular degeneration (nAMD) by inhibiting angiopoietin-2 (ANG-2), a key mediator of vascular instability and inflammation in the retina. By blocking ANG-2, this antibody helps reduce abnormal blood vessel growth, vascular leakage, and retinal edema. It is often explored in combination with VEGF inhibitors to provide broader protection against ocular neovascularization and improve visual outcomes. Also under investigation for other retinal diseases such as diabetic macular edema and retinal vein occlusion. Its high specificity and humanized design support targeted therapy with potentially fewer off-target effects.